PRINCETON, N.J., June 28, 2011 /PRNewswire/ -- GE Healthcare today announced the availability of DaTscan™ (Ioflupane I 123 Injection), in more than 80 hospitals across the US. DaTscan is the first FDA ...

DaTscan is a radioactive diagnostic agent that works by binding reversibly to the human dopamine transporter (DaT) in the brain. The Food and Drug Administration (FDA) has expanded the approval of ...

The FDA has approved DaTscan (Ioflupane I 123 Injection, from GE Healthcare) for use with single photon emission computed tomography (SPECT) imaging, for the detection of dopamine transporters (DaT) ...

Thanks to a new diagnostic imaging technique, physicians now have an objective test to evaluate patients for parkinsonian syndromes, such as Parkinson's disease. Northwestern Memorial Hospital is ...

January 17, 2011 — GE Healthcare has announced Food and Drug Administration (FDA) approval of ioflupane iodine-123 injection (DaTscan), a contrast agent for use with single-photon emission computed ...

DaTscan is a radiopharmaceutical imaging agent that works by binding to dopamine transporters (DaT) in the brain. A specific marker for DaT, DaTscan produces images that provide visual evidence based ...

A new scan to help in difficult-to-diagnose cases of Parkinson’s disease or other parkinsonian syndromes is available at more than 80 U.S. hospitals, including some in the Chicago area, since ...

ST. LOUIS, April 05, 2022 (GLOBE NEWSWIRE) -- Curium announced today that its generic version of DaTscan (Ioflupane I 123 Injection) was approved on March 30, 2022, by the U.S. Food and Drug ...

The DaTscan, a special type of dopamine transporter imaging brain scan, may help doctors predict how a newly diagnosed patient’s Parkinson’s disease will progress, researchers from the University of ...